Overview

ILF With/Without Cisplatin for Advanced Gastric Cancer

Status:
Unknown status
Trial end date:
2007-03-01
Target enrollment:
Participant gender:
Summary
To compare the combination of irinotecan, leucovorin and 5-FU (ILF) with ILF plus cisplatin (PILF) as first-line chemotherapy in patients with measurable metastatic gastric cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Gachon University Gil Medical Center
Treatments:
Cisplatin
Irinotecan